Clinical Trials on Advanced Pancreatic Ductal Adenocarcinoma (Optional, Dose Expansion, Not Initiated)

Total 195 results

Bayer

Completed

First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin

Advanced Recurrent Malignant Pleural Epithelioid Mesothelioma | Advanced Recurrent Malignant Peritoneal Epithelioid Mesothelioma | Advanced Recurrent Serous Ovarian Cancer | Advanced Pancreatic Ductal Adenocarcinoma (Optional, Dose Expansion, Not Initiated)

United States, Sweden, Netherlands, United Kingdom, Finland
Georgetown University
ERYtech Pharma

Active, not recruiting

Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma

Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma

United States
Roswell Park Cancer Institute

Not yet recruiting

FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal Adenocarcinoma and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study

Borderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma

United States
Jonsson Comprehensive Cancer Center
Arcus Biosciences, Inc.

Suspended

Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

Borderline Resectable Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Recruiting

Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.

Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

United States
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Active, not recruiting

KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma.

Advanced Pancreatic Ductal Adenocarcinoma

China
University of Malaya

Recruiting

Combined S-1 With DC+CIK As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma

Advanced Solid Tumor | Pancreatic Ductal Adenocarcinoma

Malaysia
Bruno Bockorny
Dana-Farber Cancer Institute; Agenus Inc.

Not yet recruiting

AGEN1423 Plus Balstilimab With or Without Chemo in Pancreatic Cancer

Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma | Advanced Pancreatic Ductal Adenocarcinoma

United States
John Lenehan

Not yet recruiting

CHemotherapy And Stool Transplant in PDAC (CHASe-PDAC) (CHASe-PDAC)

Unresectable or Metastatic Advanced Pancreatic Ductal Adenocarcinoma

Canada
OHSU Knight Cancer Institute
Genentech, Inc.; Oregon Health and Science University; American Association for... and other collaborators

Recruiting

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal Adenocarcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer

Stage III Pancreatic Cancer AJCC v8 | Borderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma

United States
OHSU Knight Cancer Institute
Oregon Health and Science University

Not yet recruiting

Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Adenocarcinoma

United States
Flemming Forsberg
National Cancer Institute (NCI)

Recruiting

Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Unresectable...

United States, Norway
Brandon Huffman
Stand Up To Cancer; Lustgarten Foundation; K-Group, Beta, Inc., a wholly owned...

Recruiting

ZN-c3 + Gemcitabine in Pancreatic Cancer

Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma | Advanced Pancreatic Adenocarcinoma

United States
Jun Gong, MD
Emmaus Medical, Inc.

Active, not recruiting

Trial of First-line L-glutamine With Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer

Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma | Advanced Pancreatic Adenocarcinoma

United States
Memorial Sloan Kettering Cancer Center

Recruiting

Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)

Pancreatic Cancer | Pancreatic Cancer Metastatic | Pancreatic Cancer Stage IV | Metastatic Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Pancreatic Carcinoma | Metastatic Pancreatic Cancer | Pancreatic Cancer Non-resectable | Metastatic Pancreatic Ductal Adenocarcinoma | Pancreatic Carcinoma... and other conditions

United States
University of Utah
National Cancer Institute (NCI)

Recruiting

Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (SHAPER) (SHAPER)

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Borderline Resectable Pancreatic Adenocarcinoma | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8 | Locally Advanced Unresectable Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Ductal...

United States
GERCOR - Multidisciplinary Oncology Cooperative...
OSE Immunotherapeutics

Recruiting

Maintenance With OSE2101 Plus FOLFIRI, or FOLFIRI After FOLFIRINOX-based Induction Therapy in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (TEDOPAM)

Metastatic Cancer | Pancreatic Ductal Adenocarcinoma | Locally Advanced Cancer

France
Memorial Sloan Kettering Cancer Center
Halozyme Therapeutics; Miami Cancer Institute

Active, not recruiting

Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma

Pancreatic Cancer | Advanced Pancreatic Ductal Adenocarcinoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8 | Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal Adenocarcinoma

United States
Changhai Hospital

Recruiting

Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer

Pancreatic Neoplasms | Pancreatic Cancer | Advanced Cancer | Pancreatic Ductal Adenocarcinoma

China
AIO-Studien-gGmbH
Servier; Institut für Klinisch-Onkologische Forschung der Krankenhaus Nordwest...

Active, not recruiting

Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer (NIFE)

Biliary Tract Cancer | Extrahepatic Bile Duct Carcinoma | Non-Resectable Hepatocellular Carcinoma | Adenocarcinoma Metastatic | Adenocarcinoma of the Biliary Tract | Adenocarinoma Locally Advanced | Intrahepatic Bile Duct Carcinoma

Germany
University Health Network, Toronto
Johns Hopkins University; Memorial Sloan Kettering Cancer Center; Dana-Farber... and other collaborators

Active, not recruiting

Pancreatic Adenocarcinoma Signature Stratification for Treatment (PASS-01)

Pancreatic Cancer Metastatic | Pancreatic Ductal Adenocarcinoma | Advanced Pancreatic Cancer

United States, Canada
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer

Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Advanced Pancreatic Adenocarcinoma | Unresectable Pancreatic Ductal Adenocarcinoma

United States
German Cancer Research Center
University Hospital Heidelberg

Recruiting

A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients With Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma (IntenSify)

Pancreatic Cancer | Pancreatic Adenocarcinoma | CYP3A Inhibitor | Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma | Pancreatic Neoplasm

Germany
Academisch Medisch Centrum - Universiteit van Amsterdam...
M.D. Anderson Cancer Center; University of Colorado, Denver; Radboud University... and other collaborators

Recruiting

PREOPANC-4 Implementation Program for Locally Advanced Pancreatic Cancer (PREOPANC-4)

Pancreatic Cancer | Chemotherapy Effect | Locally Advanced Pancreatic Adenocarcinoma | Pancreatic Adenocarcinoma Non-resectable

Netherlands
Dana-Farber Cancer Institute
NH TherAguix SAS

Recruiting

Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer

Non-small Cell Lung Cancer | Advanced Pancreatic Adenocarcinoma | Unresectable Pancreatic Cancer | Ductal Adenocarcinoma of the Pancreas

United States
National Cancer Institute (NCI)

Active, not recruiting

Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery

Pancreatic Ductal Adenocarcinoma | Stage III Pancreatic Cancer AJCC v6 and v7 | Stage IV Pancreatic Cancer AJCC v6 and v7 | Pancreatic Acinar Cell Carcinoma | Locally Advanced Pancreatic Adenocarcinoma

United States
University Health Network, Toronto

Recruiting

FAZA PET/MRI Pancreas

Locally Advanced Pancreatic Adenocarcinoma | Unresectable Pancreatic Cancer | Pancreatic Adenocarcinoma Non-resectable

Canada
UNC Lineberger Comprehensive Cancer Center

Recruiting

Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer

Pancreatic Neoplasms | Pancreas Adenocarcinoma | Pancreatic Cancer Resectable | Cancer of Pancreas | Pancreatic Cancer Non-resectable | Pancreatic Ductal Adenocarcinoma (PDAC) | Pancreatic Cancer, Adult

United States
Phanes Therapeutics

Recruiting

Dose Escalation/Expansion Study of PT199 (an Anti-CD73 mAb) Administered Alone and in Combination With a PD-1 Inhibitor (the MORNINGSTAR Study)

Non Small Cell Lung Cancer | Pancreatic Ductal Adenocarcinoma

United States
University of Washington

Completed

Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer

Advanced Malignant Solid Neoplasm | Recurrent Pancreatic Carcinoma | Stage III Pancreatic Cancer AJCC v6 and v7 | Recurrent Malignant Solid Neoplasm | Stage IVA Pancreatic Cancer | Stage IVB Pancreatic Cancer | Bile Duct Carcinoma

United States
Wuhan Union Hospital, China

Not yet recruiting

Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer

Pancreatic Cancer | Pancreatic Cancer Non-resectable | Pancreatic Ductal Adenocarcinoma, PDAC

China
City of Hope Medical Center

Recruiting

Pancreatic Cancer Detection Consortium (PCDC)

Pancreatic Neoplasms | Pancreatic Cancer | Pancreatic Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer Resectable | Pancreatic Carcinoma | Pancreatic Cancer Non-resectable | Pancreatic Cancer Stage III | Pancreatic Cancer Stage | Pancreatic Cancer Stage II | Pancreatic Cancer, Adult | Pancreatic... and other conditions

Korea, Republic of, United States, Japan
University Hospital, Ghent

Completed

Feasibility of Radiotherapy and Concomitant Gemcitabine and Oxaliplatin in Locally Advanced Pancreatic Cancer and Distal Cholangiocarcinoma

Locally Advanced and Unresectable, But Non-metastatic Pancreatic Adenocarcinoma or Cholangiocarcinoma

Belgium
University of Oxford
National Institute for Health Research, United Kingdom; Imunon

Withdrawn

PanDox: Targeted Doxorubicin in Pancreatic Tumours (PanDox)

Pancreatic Cancer Metastatic | Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer Stage IV | Pancreatic Cancer Non-resectable

United Kingdom
Jacobio Pharmaceuticals Co., Ltd.

Recruiting

Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation

Colorectal Cancer | Non-small Cell Lung Cancer | Pancreatic Ductal Carcinoma | KRAS P.G12C

China
Gritstone bio, Inc.

Completed

A Study of Personalized Neoantigen Cancer Vaccines

Colorectal Cancer | Non Small Cell Lung Cancer | Gastroesophageal Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Urothelial Carcinoma

United States
Northwestern University
National Cancer Institute (NCI)

Recruiting

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

Advanced Malignant Solid Neoplasm | Advanced Pancreatic Carcinoma | Metastatic Pancreatic Carcinoma | Refractory Pancreatic Carcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer... and other conditions

United States
Affini-T Therapeutics, Inc.

Recruiting

Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor

Colorectal Cancer | Non-Small Cell Lung Cancer | Solid Tumor | Pancreatic Ductal Adenocarcinoma | KRAS G12V

United States
Deciphera Pharmaceuticals LLC

Recruiting

Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

Melanoma | Non-Small Cell Lung Cancer | Advanced Solid Tumor | Pancreatic Ductal Adenocarcinoma | BRAF Gene Mutation | RAS Mutation | NF1 Mutation | RAF Mutation | CRAF Gene Mutation

United States
Genentech, Inc.
Chugai Pharmaceutical Co.

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Gastric Cancer | Metastatic Solid Tumor | Non-small Cell Lung Cancer | Pancreatic Ductal Adenocarcinoma

Korea, Republic of, Spain, Japan, New Zealand, Australia, United States, Italy, Brazil
Taiho Pharmaceutical Co., Ltd.

Recruiting

AB122 Platform Study

Gastric Cancer | Colorectal Cancer | Non-small Cell Lung Cancer | Pancreatic Ductal Adenocarcinoma | Alveolar Soft Part Sarcoma | Advanced or Metastatic Solid Tumor

Japan
Pfizer

Not yet recruiting

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

Carcinoma, Non-Small-Cell Lung | Colorectal Neoplasms | Carcinoma, Pancreatic Ductal
University of Chicago
National Cancer Institute (NCI)

Completed

Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies

Mucinous Adenocarcinoma of the Rectum | Signet Ring Adenocarcinoma of the Rectum | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Acinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Stage III Pancreatic Cancer | Stage IV Pancreatic... and other conditions

United States
Revolution Medicines, Inc.

Recruiting

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Advanced Solid Tumors | Non-small Cell Lung Cancer (NSCLC) | Pancreatic Ductal Adenocarcinoma (PDAC) | Colorectal Cancer (CRC)

United States
Revolution Medicines, Inc.

Recruiting

Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors

Advanced Solid Tumors | Non-small Cell Lung Cancer (NSCLC) | Pancreatic Ductal Adenocarcinoma (PDAC) | Colorectal Cancer (CRC)

United States
Mirati Therapeutics Inc.

Recruiting

Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

Pancreatic Adenocarcinoma | Solid Tumor | Advanced Solid Tumor | Non-small Cell Lung Cancer | Colo-rectal Cancer

United States
The Rogosin Institute
Vital Systems Inc.

Completed

Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic/Colorectal Cancer (Macrobead)

Colorectal Cancer Metastatic | Pancreatic Adenocarcinoma Metastatic | Pancreatic Adenocarcinoma Non-resectable

United States

Clinical Trials on Advanced Pancreatic Ductal Adenocarcinoma (Optional, Dose Expansion, Not Initiated)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations